Gedeon Richter Share Price OTC Markets

Equities

RGEDF

HU0000123096

Pharmaceuticals

Market Closed - OTC Markets 07:23:33 06/06/2024 pm IST 5-day change 1st Jan Change
24.9 USD -5.66% Intraday chart for Gedeon Richter 0.00% +0.22%

Financials

Sales 2024 * 83TCr 223.29Cr 19TCr Sales 2025 * 91TCr 246.9Cr 21TCr Capitalization 1,70000Cr 458.94Cr 38TCr
Net income 2024 * 24TCr 65Cr 5.46TCr Net income 2025 * 27TCr 73Cr 6.06TCr EV / Sales 2024 * 1.9 x
Net cash position 2024 * 13TCr 34Cr 2.87TCr Net cash position 2025 * 19TCr 53Cr 4.4TCr EV / Sales 2025 * 1.65 x
P/E ratio 2024 *
7.05 x
P/E ratio 2025 *
6.43 x
Employees 11,603
Yield 2024 *
6.01%
Yield 2025 *
6.37%
Free-Float 72.67%
More Fundamentals * Assessed data
Dynamic Chart
Gedeon Richter plc announces Directorate Changes CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Q4 2023 Earnings Call, Feb 29, 2024
Gedeon Richter plc announces Board Changes, Effective 1 March 2024 CI
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million MT
GRANATA BIO Corp announced that it has received $14 million in funding from GV Management Company, LLC, CooperSurgical, Inc., Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Alumni Ventures Group, LLC, Vibe Biotechnology Inc., Amboy Street Ventures and other investors. CI
Mithra Signs Agreement with Gedeon Richter for Commercialization of Estelle, Donesta in China MT
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Q3 2023 Earnings Call, Nov 08, 2023
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for  Commercialisation of RYEQO® CI
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis CI
GRANATA BIO Corp announced that it expects to receive $15.590561 million in funding CI
Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of Endometriosis CI
More news
1 day-5.66%
Current month-9.27%
1 month-11.65%
3 months-6.97%
6 months+0.22%
Current year+0.22%
More quotes
1 month
24.01
Extreme 24.005
27.45
Current year
24.01
Extreme 24.005
29.58
1 year
21.47
Extreme 21.47
29.58
3 years
13.05
Extreme 13.05
31.00
5 years
13.05
Extreme 13.05
31.00
10 years
12.85
Extreme 12.85
31.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 -
Director of Finance/CFO 57 01/22/01
Chief Tech/Sci/R&D Officer 64 01/84/01
Members of the board TitleAgeSince
Chief Executive Officer 45 -
Director of Finance/CFO 57 01/22/01
Chairman 88 01/08/01
More insiders
Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9,300 HUF
Average target price
11,800 HUF
Spread / Average Target
+26.89%
Consensus

Quarterly revenue - Rate of surprise